MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct
Author(s) -
Ruchi Jain,
Josh P. Frederick,
Eric YiHsiu Huang,
Kristine Burke,
David Mauger,
Elizaveta A. Andrianova,
Sam Farlow,
Summar Siddiqui,
Jeffrey Pimentel,
Kahlin Cheung-Ong,
Kristine McKinney,
Caroline Köhrer,
Melissa J. Moore,
Tirtha Chakraborty
Publication year - 2018
Publication title -
nucleic acid therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.255
H-Index - 67
eISSN - 2159-3345
pISSN - 2159-3337
DOI - 10.1089/nat.2018.0734
Subject(s) - puma , microrna , apoptosis , transfection , biology , cancer cell , cancer research , monoclonal antibody , messenger rna , hepatocellular carcinoma , intracellular , immune system , cancer , microbiology and biotechnology , antibody , cell culture , immunology , gene , biochemistry , genetics
The advent of therapeutic mRNAs significantly increases the possibilities of protein-based biologics beyond those that can be synthesized by recombinant technologies (eg, monoclonal antibodies, extracellular enzymes, and cytokines). In addition to their application in the areas of vaccine development, immune-oncology, and protein replacement therapies, one exciting possibility is to use therapeutic mRNAs to program undesired, diseased cells to synthesize a toxic intracellular protein, causing cells to self-destruct. For this approach to work, however, methods are needed to limit toxic protein expression to the intended cell type. Here, we show that inclusion of microRNA target sites in therapeutic mRNAs encoding apoptotic proteins, Caspase or PUMA, can prevent their expression in healthy hepatocytes while triggering apoptosis in hepatocellular carcinoma cells.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom